1
|
Shahed H, Sharma N, Angst M, Voigt J, Perßon J, Prakash P, Törnroos KW, Chernyshov D, Gildenast H, Ohl M, Saffarini G, Grzechnik A, Friese K. Structural insight into the cooperativity of spin crossover compounds. Acta Crystallogr B Struct Sci Cryst Eng Mater 2023; 79:354-367. [PMID: 37578185 PMCID: PMC10552598 DOI: 10.1107/s2052520623005814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 07/02/2023] [Indexed: 08/15/2023]
Abstract
Spin-crossover (SCO) compounds are promising materials for a wide variety of industrial applications. However, the fundamental understanding of their nature of transition and its effect on the physical properties are still being fervently explored; the microscopic knowledge of their transition is essential for tailoring their properties. Here an attempt is made to correlate the changes in macroscopic physical properties with microscopic structural changes in the orthorhombic and monoclinic polymorphs of the SCO compound Fe(PM-Bia)2(NCS)2 (PM = N-2'-pyridylmethylene and Bia = 4-aminobiphenyl) by employing single-crystal X-ray diffraction, magnetization and DSC measurements. The dependence of macroscopic properties on cooperativity, highlighting the role of hydrogen bonding, π-π and van der Waals interactions is discussed. Values of entropy, enthalpy and cooperativity are calculated numerically based on the Slichter-Drickamer model. The particle size dependence of the magnetic properties is probed along with the thermal exchange and the kinetic behavior of the two polymorphs based on the dependence of magnetization on temperature scan rate and a theoretical model is proposed for the calculation of the non-equilibrium spin-phase fraction. Also a scan-rate-dependent two-step behavior observed for the orthorhombic polymorph, which is absent for the monoclinic polymorph, is reported. Moreover, it is found that the radiation dose from synchrotron radiation affects the spin-crossover process and shifts the transition region to lower temperatures, implying that the spin crossover can be tuned with radiation damage.
Collapse
Affiliation(s)
- H. Shahed
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
- Institute of Crystallography, RWTH Aachen University, Jägerstr. 17-19, 52066 Aachen, Germany
| | - N. Sharma
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | - M. Angst
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | - J. Voigt
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | - J. Perßon
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | - P. Prakash
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | - K. W. Törnroos
- Department of Chemistry, University of Bergen, Allégaten 41, N-5007 Bergen, Norway
| | - D. Chernyshov
- Swiss–Norwegian Beamlines at the European Synchrotron Radiation Facility, 38000 Grenoble, France
| | - H. Gildenast
- Institute of Inorganic Chemistry, RWTH Aachen University, 52074 Aachen, Germany
| | - M. Ohl
- Jülich Centre for Neutron Science (JCNS-1), Forschungszentrum Jülich, 52425 Jülich, Germany
- Department of Materials Science and Engineering, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - G. Saffarini
- Physics Department, An-Najah National University, Nablus, Palestine
| | - A. Grzechnik
- Institute of Crystallography, RWTH Aachen University, Jägerstr. 17-19, 52066 Aachen, Germany
- Jülich Centre for Neutron Science (JCNS-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | - K. Friese
- Jülich Centre for Neutron Science (JCNS-2) and Peter Grünberg Institute (PGI-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
- Institute of Crystallography, RWTH Aachen University, Jägerstr. 17-19, 52066 Aachen, Germany
| |
Collapse
|
2
|
Shahed H, Sharma N, Angst M, Voigt J, Persson J, Gildenast H, Englert U, Chernyshov D, Tornroos K, Grzechnik A, Friese K. Elucidation of barocaloric effect in spin crossover compounds. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322092932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
3
|
Hakala B, Manousou D, Glazyrin K, Crichton W, Friese K, Grzechnik A. Crystal structures of V 2O 5 and V 6O 13 at high pressures: implications for the Wadsley phase family behaviour under extreme conditions. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322091215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
4
|
Wienke A, Friese K. Rechtliche Aspekte der Digitalisierung in der Medizin. Nuklearmedizin 2018; 57:VI-VIII. [DOI: 10.1055/s-0038-1676686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Die Digitalisierung unserer Gesellschaft, unseres Handelns und unseres Denkens wird allerorten diskutiert; in Anlehnung an ein literarisch bekannt gewordenes gallisches Dorf könnte man meinen, dass sich nur wenige Unbeugsame dem digitalen Zeitalter entgegenstemmen. Auch und gerade im Gesundheitswesen ist die Digitalisierung derzeit eines der brennendsten Themen in der Gesundheitspolitik und in aktuellen Gesetzgebungsverfahren. So hat die Bundesregierung im Koalitionsvertrag vom 14.03.2018 festgehalten, dass bis 2020 ein Aktionsplan mit konkreten Maßnahmen entwickelt werden soll. Auch die aktuellen Diskussionen um die Einführung und den Nutzungsumfang der elektronischen Gesundheitskarte dominieren weiterhin in den Medien. Nicht zu vergessen ist auch die Debatte um die Lockerung des Fernbehand-lungsverbotes, für welche sich eine große Mehrheit auf dem 121. Ärztetag im Mai 2018 ausgesprochen hat. Letztlich nimmt das Thema Digitalisierung durch die damit einhergehenden datenschutzrechtlichen Fragen an Fahrt auf; wer denkt dieser Tage dabei nicht an die EU-Datenschutzgrundverordnung (DSGVO) und die Neufassung des Bundesdatenschutzgesetzes (BDSG)?
Collapse
|
5
|
Wienke A, Friese K. [Legal aspects of digitalization in the medical sector]. Laryngorhinootologie 2018; 97:713-716. [PMID: 30340229 DOI: 10.1055/a-0652-6505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Herrmann MG, Stoffel RP, Dronskowski R, Friese K. The low-temperature heat capacity of the Sb 2Te 3-x Se x solid solution from experiment and theory. J Phys Condens Matter 2018; 30:405702. [PMID: 30168444 DOI: 10.1088/1361-648x/aade0e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The lattice dynamics of Sb2Te3-x Se x (x = 0, 0.6, 1.2, 1.8, 3) mixed crystals have been studied by a combination of low-temperature heat-capacity measurements between 2-300 K and first-principles calculations. The results from the experimental and theoretical investigations are in excellent agreement. While Sb2Se3 can be considered as a harmonic lattice oscillator in this temperature range, for the isostructural compounds Sb2Te3, Sb2Se0.6Te2.4, Sb2Se1.2Te1.8 and Sb2Se1.8Te1.2 (tetradymite structure type; R [Formula: see text] m) a small anharmonic contribution to the total heat capacity has to be taken into account at temperatures above 250 K. For the compounds which crystallize in the tetradymite structure type the experimental and theoretical data show unambiguously that the exchange of Te by Se leads to an increase of the bonding polarity and consequently to a hardening of the bonding which is reflected in an increase of the Debye temperatures with increasing Se contents. In addition, our studies clearly demonstrate that the mixed crystals in the stability field of the tetradymite structure type are characterized by a strong non-ideal mixing behavior.
Collapse
Affiliation(s)
- M G Herrmann
- Jülich Centre for Neutron Science-2/Peter Grünberg Institut-4, Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| | | | | | | |
Collapse
|
7
|
Jaeger BAS, Neugebauer J, Andergassen U, Melcher C, Schochter F, Mouarrawy D, Ziemendorff G, Clemens M, V Abel E, Heinrich G, Schueller K, Schneeweiss A, Fasching P, Beckmann MW, Scholz C, Friedl TWP, Friese K, Pantel K, Fehm T, Janni W, Rack B. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLoS One 2017; 12:e0173593. [PMID: 28586395 PMCID: PMC5460789 DOI: 10.1371/journal.pone.0173593] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2016] [Accepted: 02/22/2017] [Indexed: 12/14/2022] Open
Abstract
Background HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients with HER2-positive primary breast cancer at the time of diagnosis. Aim of the study was to assess potential discordance of HER2 status between primary tumor and CTCs, as this may have important implications for the use of HER2-targeted therapy. Methods The number and HER2 status of CTCs out of 30ml peripheral blood were assessed in 642 patients using the CellSearch System (Janssen Diagnostics, USA). The cutoff for CTC positivity was the presence of at least 1 CTC, and the cutoff for HER2 positivity of CTCs was the presence of at least 1 CTC with a strong HER2 staining. Results 258 (40.2%) of the 642 patients were positive for CTCs (median 2; range 1–1,689). 149 (57.8%) of these 258 patients had at least 1 CTC with strong HER2 staining. The presence of HER2-positive CTCs was not associated with tumor size (p = 0.335), histopathological grading (p = 0.976), hormone receptor status (ER: p = 0.626, PR: p = 0.263) or axillary lymph node involvement (p = 0.430). Overall, 83 (32.2%) of the CTC-positive patients exclusively had CTCs with strong HER2 staining, whereas 31 (12.0%) had only CTCs with negative HER2 staining. Within-sample variation in the HER2 status of CTCs was found in 86 (57.8%) of the 149 patients with more than 1 CTC. Conclusion This study demonstrated that discordance between the HER2 expression of CTCs and that of the primary tumor frequently occurs in early breast cancer. Future follow-up evaluation will assess whether this discrepancy may contribute to trastuzumab resistance.
Collapse
Affiliation(s)
- B A S Jaeger
- Department of Gynecology and Obstetrics, Heinrich-Heine-University Hospital, Duesseldorf, Germany
| | - J Neugebauer
- Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Hospital, Munich, Germany
| | - U Andergassen
- Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Hospital, Munich, Germany
| | - C Melcher
- Department of Gynecology and Obstetrics, Heinrich-Heine-University Hospital, Duesseldorf, Germany
| | - F Schochter
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - D Mouarrawy
- Hospital Bremerhaven-Reinkenheide, Bremerhaven, Germany
| | | | - M Clemens
- Krankenanstalten Mutterhaus der Borromäerinnen, Trier, Germany
| | - E V Abel
- Hospital Schwäbisch Gmuend, Mutlangen, Germany
| | - G Heinrich
- Praxis Dr. Heinrich, Fuerstenwalde, Germany
| | - K Schueller
- Stat-up Statistische Beratung und Dienstleistung, Munich, Germany
| | - A Schneeweiss
- Department of Gynecology and Obstetrics in the National Center for Tumor Disease, University Hospital Heidelberg, Heidelberg, Germany
| | - P Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - M W Beckmann
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - Ch Scholz
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - T W P Friedl
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - K Friese
- Hospital Bad Trissl, Bad Trissl, Germany
| | - K Pantel
- Institute for Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Fehm
- Department of Gynecology and Obstetrics, Heinrich-Heine-University Hospital, Duesseldorf, Germany
| | - W Janni
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany
| | - B Rack
- Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Hospital, Munich, Germany
| |
Collapse
|
8
|
Höhn H, Deppe C, Flemmer A, Friese K, Mahner S, Hasbargen U, Delius M. Verlauf der kindlichen Entwicklung nach Marcumartherapie in der Schwangerschaft. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Jäger B, Andergassen U, Neugebauer J, Alunni-Fabbroni M, Melcher C, Hagenbeck C, Albrecht S, Lorenz R, Decker T, Heinrich G, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Friese K, Fasching PA, Friedl TWP, Janni W, Rack BK. Persistenz zirkulierender Tumorzellen direkt nach und zwei Jahre nach adjuvanter Chemotherapie bei Patientinnen mit früher Brustkrebserkrankung – Ergebnisse der SUCCESS Studien. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Friese K, Mayr D, Kuhn C, Mahner S, Jeschke U, Heublein S. Die subzelluläre Lokalisation des G-Protein-gekoppelten-Estrogenrezeptors als Prognoseparameter des frühen Zervixkarzinoms. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Dobler F, Delius M, Lehner M, Bayer A, Herber-Jonat S, Schulze A, Flemmer AW, Dostert S, Friese K, Mahner S, Hasbargen U. EXIT bei Pierre-Robin-Sequenz – Fallbericht zu perinatalem Management einer Hochrisikogeburt. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Kolben TM, Dannecker C, Baltateanu K, Goess C, Starrach T, Semmlinger A, Ditsch N, Gallwas J, Mahner S, Friese K, Kolben T. HPV Vaccination: Attitude and Knowledge among German Gynecologists. Geburtshilfe Frauenheilkd 2016; 76:1074-1080. [PMID: 27761028 PMCID: PMC5065419 DOI: 10.1055/s-0042-112813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 07/17/2016] [Accepted: 07/18/2016] [Indexed: 10/20/2022] Open
Abstract
Purpose: In order to achieve a higher vaccination rate, education on HPV as well as options for prophylaxis performed by doctors is of great importance. One opportunity to increase the protection against HPV would be vaccinating boys. This study evaluated attitude and knowledge among German gynecologists regarding HPV vaccination, especially in boys. Material and Methods: A questionnaire with 42 questions about demographics, attitude and knowledge about HPV and HPV vaccination was sent to members of the German Society for Gynecology and Obstetrics (DGGG). Results: 998 out of 6567 addressed gynecologists participated. Knowledge about HPV, associated diseases and possible HPV vaccines was high among participants. The attitude towards vaccination in boys as well as girls was positive. Only 8.2 % refused to vaccinate their sons whereas 2.2 % refused to do this for their daughters. However, only few gynecologists vaccinated their daughters and sons against HPV. Main reason for girls was an age outside of vaccination guidelines; for boys it was the lack of cost coverage. Conclusion: The willingness of gynecologists to perform HPV vaccination in boys is as high as for girls. However, sons of gynecologists are only rarely vaccinated against HPV. Main reason is the lack of cost coverage. Vaccinating boys could decrease the disease burden in males, as well as protect women by interrupting ways of transmission. Since the main argument against vaccination of boys is only of financial nature, the necessity of a vaccination recommendation for boys needs to be re-evaluated taking into account the cost-reduced 2-dose vaccination scheme.
Collapse
Affiliation(s)
- T. M. Kolben
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - C. Dannecker
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - K. Baltateanu
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - C. Goess
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - T. Starrach
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - A. Semmlinger
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - N. Ditsch
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - J. Gallwas
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - S. Mahner
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - K. Friese
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| | - T. Kolben
- Department for Obstetrics and Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|
13
|
Friese K, Kuhn C, Mahner S, Jeschke U, Heublein S. Cytoplasmic GPER predicts excellent overall and progression free survival in early stage cervical cancer. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1580661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Grzechnik A, Ueda Y, Yamauchi T, Hanfland M, Hering P, Potapkin V, Friese K. Pressure-induced non-superconducting phase of β-Na0.33V2O5 and the mechanism of high-pressure phase transitions in β-Na0.33V2O5 and β-Li0.33V2O5 at room temperature. J Phys Condens Matter 2016; 28:035401. [PMID: 26702603 DOI: 10.1088/0953-8984/28/3/035401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
The crystal structure of β-Na0.33V2O5 (C2/m, Z = 6) has been studied on compression to 19 GPa at room temperature using synchrotron single-crystal diffraction in a diamond anvil cell. The vanadate bronze undergoes a phase transition to a non-superconducting phase at about 12 GPa due to changes of polyhedral connectivities in the vanadate framework and due to ordering of the Na(+) cations. This novel structure (Cm, Z = 6) is interpreted as an intermediate stage in the sequence of pressure-induced transformations in the β-A0.33V2O5 bronzes (A: Li, Na) at room temperature. This study reveals the close relation between the loss of the two-leg ladder V-V system and non-superconducting state of the β-A0.33V2O5 materials.
Collapse
Affiliation(s)
- A Grzechnik
- Institute of Crystallography, RWTH Aachen University, 52060 Aachen, Germany
| | | | | | | | | | | | | |
Collapse
|
15
|
Knabl J, Kainer F, Geiger P, Bergauer F, Riedel C, Friese K, Kirn V. Cervical conisation and the risk of preterm delivery: a retrospective matched pair analysis of a German cohort. Z Geburtshilfe Neonatol 2015. [DOI: 10.1055/s-0035-1566554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Mendling W, Brasch J, Cornely OA, Effendy I, Friese K, Ginter-Hanselmayer G, Hof H, Mayser P, Mylonas I, Ruhnke M, Schaller M, Weissenbacher ER. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses 2015; 58 Suppl 1:1-15. [PMID: 25711406 DOI: 10.1111/myc.12292] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The oestrogenised vagina is colonised by Candida species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this increases to at least 30%. In most cases, Candida albicans is involved. Host factors, particularly local defence mechanisms, gene polymorphisms, allergies, serum glucose levels, antibiotics, psycho-social stress and oestrogens influence the risk of candidal vulvovaginitis. Non-albicans species, particularly Candida glabrata, and in rare cases also Saccharomyces cerevisiae, cause less than 10% of all cases of vulvovaginitis with some regional variation; these are generally associated with milder signs and symptoms than normally seen with a C. albicans-associated vaginitis. Typical symptoms include premenstrual itching, burning, redness and odourless discharge. Although itching and redness of the introitus and vagina are typical symptoms, only 35-40% of women reporting genital itching in fact suffer from vulvovaginal candidosis. Medical history, clinical examination and microscopic examination of vaginal content using 400× optical magnification, or preferably phase contrast microscopy, are essential for diagnosis. In clinically and microscopically unclear cases and in chronically recurring cases, a fungal culture for pathogen determination should be performed. In the event of non-C. albicans species, the minimum inhibitory concentration (MIC) should also be determined. Chronic mucocutaneous candidosis, a rarer disorder which can occur in both sexes, has other causes and requires different diagnostic and treatment measures. Treatment with all antimycotic agents on the market (polyenes such as nystatin; imidazoles such as clotrimazole; and many others including ciclopirox olamine) is easy to administer in acute cases and is successful in more than 80% of cases. All vaginal preparations of polyenes, imidazoles and ciclopirox olamine and oral triazoles (fluconazole, itraconazole) are equally effective (Table ); however, oral triazoles should not be administered during pregnancy according to the manufacturers. C. glabrata is not sufficiently sensitive to the usual dosages of antimycotic agents approved for gynaecological use. In other countries, vaginal suppositories of boric acid (600 mg, 1-2 times daily for 14 days) or flucytosine are recommended. Boric acid treatment is not allowed in Germany and flucytosine is not available. Eight hundred-milligram oral fluconazole per day for 2-3 weeks is therefore recommended in Germany. Due to the clinical persistence of C. glabrata despite treatment with high-dose fluconazole, oral posaconazole and, more recently, echinocandins such as micafungin are under discussion; echinocandins are very expensive, are not approved for this indication and are not supported by clinical evidence of their efficacy. In cases of vulvovaginal candidosis, resistance to C. albicans does not play a significant role in the use of polyenes or azoles. Candida krusei is resistant to the triazoles, fluconazole and itraconazole. For this reason, local imidazole, ciclopirox olamine or nystatin should be used. There are no studies to support this recommendation, however. Side effects, toxicity, embryotoxicity and allergies are not clinically significant. Vaginal treatment with clotrimazole in the first trimester of a pregnancy reduces the rate of premature births. Although it is not necessary to treat a vaginal colonisation of Candida in healthy women, vaginal administration of antimycotics is often recommended in the third trimester of pregnancy in Germany to reduce the rate of oral thrush and napkin dermatitis in healthy full-term newborns. Chronic recurrent vulvovaginal candidosis continues to be treated in intervals using suppressive therapy as long as immunological treatments are not available. The relapse rate associated with weekly or monthly oral fluconazole treatment over 6 months is approximately 50% after the conclusion of suppressive therapy according to current studies. Good results have been achieved with a fluconazole regimen using an initial 200 mg fluconazole per day on 3 days in the first week and a dosage-reduced maintenance therapy with 200 mg once a month for 1 year when the patient is free of symptoms and fungal infection (Table ). Future studies should include Candida autovaccination, antibodies to Candida virulence factors and other immunological experiments. Probiotics with appropriate lactobacillus strains should also be examined in future studies on the basis of encouraging initial results. Because of the high rate of false indications, OTC treatment (self-treatment by the patient) should be discouraged.
Collapse
Affiliation(s)
- Werner Mendling
- Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Vogelsangstrasse 106, 42109 Wuppertal, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Wiest I, Alexiou C, Friese K, Tübel J, Mayr D, Betz P, Freier C, Dian D, Jeschke U, Weißenbacher T. TA-MUC1 und der humanisierte Antikörper Pankomab-GEX TM – Fächerübergreifender Benefit von Ergebnissen aus der gynäkologischen Onkologie am Beispiel des Larynxkarzinoms. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Freier CP, Kuhn C, Rapp M, Endres S, Mayr D, Friese K, Anz D, Jeschke U. Expression of CCL22 and Infiltration by Regulatory T Cells are increased in the Decidua of Human Miscarriage Placentas. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
19
|
Scholz C, Andergassen U, Hepp P, Schindlbeck C, Friedl TWP, Harbeck N, Kiechle M, Sommer H, Hauner H, Friese K, Rack B, Janni W. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer. Breast Cancer Res Treat 2015; 151:569-76. [DOI: 10.1007/s10549-015-3422-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Accepted: 05/07/2015] [Indexed: 12/13/2022]
|
20
|
Mendling W, Friese K, Mylonas I, Weissenbacher ER, Brasch J, Schaller M, Mayser P, Effendy I, Ginter-Hanselmayer G, Hof H, Cornely O, Ruhnke M. Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013). Geburtshilfe Frauenheilkd 2015; 75:342-354. [PMID: 27065484 PMCID: PMC4813053 DOI: 10.1055/s-0035-1545741] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
- W. Mendling
- Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe, Wuppertal
| | - K. Friese
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München
| | - I. Mylonas
- Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München
| | | | - J. Brasch
- Universitätsklinikum Kiel, Klinik für Dermatologie, Kiel
| | | | - P. Mayser
- Universitätsklinikum Giessen, Klinik für Dermatologie, Venerologie und Allergologie, Giessen
| | - I. Effendy
- Klinikum Bielefeld, Hautklinik, Bielefeld
| | | | - H. Hof
- Labor Limbach, Heidelberg
| | - O. Cornely
- Uniklinik Köln, Klinik I für Innere Medizin, Köln
| | - M. Ruhnke
- Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité, Berlin
| |
Collapse
|
21
|
Blankenstein T, Lytton SD, Leidl B, Atweh E, Friese K, Mylonas I. Point-of-care (POC) diagnosis of bacterial vaginosis (BV) using VGTest™ ion mobility spectrometry (IMS) in a routine ambulatory care gynecology clinic. Arch Gynecol Obstet 2015; 292:355-62. [PMID: 25638448 DOI: 10.1007/s00404-014-3613-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 12/30/2014] [Indexed: 01/05/2023]
Abstract
PURPOSE A new CE-marked portable desktop ion mobility spectrometer (VGTest) was used for detection of malodorous biogenic amines indicative of bacterial vaginosis (BV). This study aimed to assess the performance of this testing method for the first time in a routine ambulatory care clinic and to determine the relative levels of biogenic amines in vaginal fluid of BV. METHODS Vaginal and cervical swabs (n = 57) were surveyed for infections. Cases of BV (n = 18) confirmed positive according to "Amsel" criteria and normal controls (n = 39) showing no infection under clinical examination and testing negative in wet mount microscopy were included in the IMS analysis. RESULTS The trimethylamine (TMA) content in vaginal fluid of the BV-positive cases, AUCTMA/AUCTotal [mean 0.215 (range 0.15-0.35)] was significantly higher than normal controls [mean 0.06 (range 0.048-0.07)] p < 0.0001. The putrescine (1,4-diaminobutane, PUT) and cadaverine (1,5-diaminopentane, CAD) of BV-positive cases were above controls at borderline significance. The AUCTMA/AUCTotal ratios correlated neither with AUCPUT/AUCTotal nor AUCCAD/AUCTotal among BV-positive patients. In contrast, among normal controls all the biogenic amines were at a low level and the linear regression analysis revealed striking positive correlations of AUCTMA/AUCTotal with AUCPUT/AUCTotal (p < 0.05) and AUCCAD/AUCTotal (p < 0.001). The test shows 83 % sensitivity and 92 % specificity at a cut-off of AUCTMA/AUCTotal = 0.112 and AUC of receiver operator characteristic = 0.915 (0.81-0.97, 95 % CI). CONCLUSIONS VGTest-IMS is accurate and feasible for point-of-care testing of BV in the ambulatory care setting. Further evaluations are in progress to assess the utility of VGTest-IMS for differential diagnosis of candidosis, non-BV infection and common inflammatory conditions.
Collapse
Affiliation(s)
- T Blankenstein
- 1st Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Maistrasse 11, 80337, Munich, Germany
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
The lattice dynamics of polycrystalline Mg(2)Ge and Mg(2)Si are compared using both microscopic and macroscopic measurements as well as theoretical calculations. The volume thermal expansion coefficient between 200 and 300 K was found to be 4.37(5) · 10(-5) K(-1) in Mg(2)Ge, compared to 3.69(5) · 10(-5) K(-1) in Mg(2)Si. Inelastic neutron scattering measurements yield densities of phonon states which are in line with theoretical calculations. The microscopic data were corroborated with macroscopic calorimetry measurements and provide quantified values for anharmonicity. The estimated macroscopic Grüneisen parameter is, γ(Mg(2)Si) = 1.17(5) and γ(Mg(2)Ge) = 1.46(5) at 295 K, in excellent agreement with Raman scattering data. Although the element specific mean force constants are practically the same, in Mg(2)Ge and Mg(2)Si, a mass homology relation alone cannot reproduce the difference in the partial densities of vibrational states in these compounds and differences in elemental bonding should be taken into account.
Collapse
Affiliation(s)
- D Bessas
- Jülich Centre for Neutron Science JCNS and Peter Grünberg Institut PGI, JARA-FIT, Forschungszentrum Jülich GmbH, D-52425 Jülich, Germany. Faculté des Sciences, Université de Liège, B-4000 Liège, Belgium. European Synchrotron Radiation Facility, F-38043, Grenoble, France
| | | | | | | | | |
Collapse
|
23
|
Andergassen U, Liesche F, Kölbl A, Jeschke U, Friese K. Glycosoltransferasen als Marker der frühen Phasen der Tumorentstehung. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
24
|
Höhn H, Friese K, Hasbargen U, Deppe C, Delius M. Case Report: Betreuung von Schwangerschaft, Geburt und Neonatalperiode bei maternaler Einnahme von Phenoprocoumon. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
25
|
Beer D, Friese K, Fürst S, Göß C, Hertlein L, Lenhard M, Grandl S, Heinemann V, Burges A. Individualized management of Aggressive Angiomyxoma: A case report. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
26
|
Heidegger HH, Weißenbacher T, Kuhn C, Wiest I, Jeschke U, Friese K. Zytokinbestimmung im Verlauf der Schwangerschaft und deren Bedeutung für neonatale Infektionen – Konzentrationsbestimmung der Zytokine IL-10, IL-12, TNF-α und Histone H2B im Fruchtwasser. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
27
|
Wolf V, Jeschke U, Pestka A, Schönfeldt VV, Kuhn C, Hofmann S, Friese K. Der membranständige Prostaglandin-Rezeptor EP3 ist ein positiver Prognostikator für Metastasierung und Überleben beim Mamma-Karzinom. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
28
|
Sela L, Mittenzwei S, Rogenhofer N, Friese K, Thaler CJ, Schönfeldt VV. Nutzen der Time-Lapse Technologie zur Identifizierung von befruchteten Eizellen mit einem zeitlich diskordant auftretenden 3. Vorkern (Pronukleus). Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
29
|
Schönfeldt VV, Rogenhofer N, Friese K, Thaler CJ, Jeschke U. Anti-Trophoblast-Antikörper (ATAK) im Serum von Patientinnen mit rezidivierenden Spontanaborten (RSA) sind Antikörper gegen Prostaglandin-E-Rezeptor-3 (EP3). Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
30
|
Jückstock JK, Brüning A, Buchholtz ML, Mylonas I, Friese K. Die Expression des Tumorsuppressorgens LDOC1 in Ovarialkarzinomzellen wird durch Promotor-Methylierung reguliert. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
31
|
Heublein S, Ebinger K, Mayr D, Friese K, Jeschke U, Lenhard M. The G-Protein Coupled Estrogen Receptor (GPER/GPR30) in ovarian granulosa cell tumors. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
32
|
Sabeth Pestka A, Knabl J, Toth B, Hüttenbrenner R, Kuhn C, Hofmann S, Wiest I, Jeschke U, Friese K. Regulation von RXRα, LXR und PPARγ in glandulären Epithelzellen der Dezidua in Aborten. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
33
|
Heublein S, Mayr D, Friese K, Jeschke U, Ditsch N. Vitamin-D-Rezeptor, Retinoid-X-Rezeptor und Peroxisom-Proliferator-aktivierter-Rezeptor-γ als Prognoseparameter für BRCA1 mutierte Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
34
|
Ulbach K, Wuerstlein R, Friese K, Harbeck N, Haberland B, Bausewein C. Befragung der Bundes- und Länderärztekammern zur Zusatz-Weiterbildung Palliativmedizin im Fach Frauenheilkunde und Geburtshilfe. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
35
|
Sela L, Mittenzwei S, Rogenhofer N, Friese K, Thaler CJ, Schönfeldt VV. Höhere Implantationsrate bei Synchronizität der 2. und 3. Furchungsteilung (t4-t3) in-vitro erzeugter Embryonen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
36
|
Kölbl A, Liesche F, Jeschke U, Friese K, Andergassen U. Die Rolle der N-acetylgalactosaminyltransferase 6 (GALNT6) in der frühen Phase der Brustkrebsentstehung und der Metastasierung. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
37
|
Heublein S, Mayr D, Friese K, Jeschke U, Lenhard M. Entwicklung eines potentiellen diagnostischen Algorithmus für die Therapiezuordnung von Ovarialkarzinompatientinnen anhand ihres Gonadotropinrezeptor-Status. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
38
|
Freier C, Endres S, Anz D, Kuhn C, Friese K, Jeschke U. Role of CCL22 in human spontaneous and repeated miscarriage. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
39
|
Knabl J, Hüttenbrenner R, Hutter S, Kirn V, Riedel C, Hofmann S, Kuhn C, Kainer F, Friese K, Jeschke U. Ist die Hochregulation der placentaren Estrogenrezeptoren α im Gestationsdiabetes Folge einer epigenetischen Regulation? Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
40
|
Schönfeldt VV, Rogenhofer N, Friese K, Jeschke U, Thaler CJ. Erhöhte Expression von Plasminogen-Aktivator-Inhibitor Typ 1 (PAI-1) im Serum von Patientinnen mit rezidivierenden Spontanaborten (RSA) und anti-Trophoblast-Antikörpern (ATAK). Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
41
|
Wiest I, Kuhn C, Hofmann S, Schulze S, Heublein S, Friese K, Dian D, Jeschke U. Der MUC1 spezifische humanisierte Antikörper PankoMab-GEX™ beeinflusst die Phosphorylierung von ErbB2 und ErbB4 in vitro. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
42
|
Mittenzwei S, Rogenhofer N, Schönfeldt VV, Friese K, Thaler C. Adrenaler Anteil am präovulatorischen Progesteronanstieg im Rahmen der kontrollierten ovariellen Hyperstimulation. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
43
|
Heublein S, Mayr D, Wiest I, Friese K, Jeschke U, Ditsch N. Immunreaktivität des Antikörpers PankoMabGEX™ ist ein unabhängiger Prognoseparameter für Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
44
|
Andergassen U, Kölbl AC, Zebisch M, Heublein S, Hutter S, Ilmer M, Schindlbeck C, Friese K, Jeschke U. Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176). Histol Histopathol 2014; 29:913-23. [PMID: 24399516 DOI: 10.14670/hh-29.913] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Disseminated tumour cells (DTCs) in the bone marrow derive from many primary tumours, such as breast cancer. Their mere existence hints to present or future metastasis and implicates a worse prognosis for the patient. DTCs may possess different characteristics in comparison to the primary tumour due to events like Epithelial-Mesenchymal-Transition. Therefore, these cells might be able to survive chemotherapy and cause relapses of the disease at a later point. We aimed to detect and further characterise DTCs by an immunostaining approach with three different antigen markers (Her-2, MUC-1 and TF, also known as CD 176). For that reason, bone marrow of 41 breast cancer patients was obtained during surgery; DTCs were enriched by density gradient centrifugation and cytospins were prepared. After fixation, immunofluorescent double-stainings were carried out with antibodies against CD176 in combination with HER-2 or MUC-1. Cells co-expressing two antigens were found in all staining combinations (Her-2 and CD176: 46.14%; MUC-1 and CD176: 18.15% of all cases). Cells that stained for a single antigen only were also found (Her-2: 36.86%; MUC-1: 34.45%; CD176: 29.65% of all cases). Significant correlations between the stainings of all markers could be shown (p<0,001). In conclusion, Thomsen-Friedenreich Antigen (TF, CD176) is a promising marker in combination with the established marker Her-2 and other markers like MUC-1. These results may serve as a basis for future DTC detection routines and help to individualize medical treatment, reducing side effects and increasing the efficiency of the therapy.
Collapse
Affiliation(s)
- U Andergassen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany
| | - A C Kölbl
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany
| | - M Zebisch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany
| | - S Heublein
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany
| | - S Hutter
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany
| | - M Ilmer
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - C Schindlbeck
- Frauenklinik - Klinikum Traunstein, Traunstein, Germany
| | - K Friese
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ludwig-Maximilians-Universität München - Campus Innenstadt, München, Germany.
| |
Collapse
|
45
|
Sann LK, Jueckstock J, Sigg W, Kaestner R, Friese K, Teubner TK. Metastasiertes Rektumkarzinom in der Schwangerschaft: ein Fallbericht. Z Geburtshilfe Neonatol 2013. [DOI: 10.1055/s-0033-1361315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
46
|
Fiori W, Renner SP, Siam K, Babapirali J, Roeder N, Dausch E, Hildebrandt T, Hillemanns P, Nehmzow M, Zygmunt M, Piroth D, Schem C, Schwenzer T, Friese K, Wallwiener D, Beckmann MW. Shaping the System - The DRG Evaluation Project of the German Society for Gynaecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, DGGG). Geburtshilfe Frauenheilkd 2013; 73:776-782. [PMID: 24771931 DOI: 10.1055/s-0033-1350748] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Revised: 07/11/2013] [Accepted: 07/18/2013] [Indexed: 10/26/2022] Open
Abstract
Introduction: The German DRG system is annually adapted to the changing services provided. For the further development, the self-governing body and its DRG Institute (InEK) depend on participation of the users. Methods: For one of the DRG evaluation projects initiated by DGGG, cost and performance data for the year 2011 from 16 hospitals were available. After plausibility checks and corrections, analyses for service and cost homogeneity were performed. In cases of inadequate DRG-representation attributes were sought that would make an appropriate reimbursement possible. Conspicuities and potential solutions were checked for clinical plausibility. Results: 44 concrete modification proposals for further development of the G-DRG system were formulated and submitted in due time to the InEK. In addition, 3 modification proposals were addressed to the German Institute for Medical Documentation and Information (Deutsches Institut für Medizinische Dokumentation und Information, DIMDI) for further development of the diagnosis classification ICD-10-GM. For all modification proposals care was taken to minimise misdirected incentives and to reduce the potential for disputes with the cost bearers and their auditors services in settlements. Discussion: The publication of the G-DRG system 2014 shows which modification proposals have been realised. Essentially, an appropriate redistribution of the resources among the gynaecological and obstetrics departments is to be expected. The financial pressure that is caused by the generally inadequate financing of hospitals will not be reduced by a further development of the G-DRG system.
Collapse
Affiliation(s)
- W Fiori
- Medizincontrolling, Geschäftsbereich Medizinisches Management, Universitätsklinikum Münster, DRG-Research-Group, Münster
| | - S P Renner
- Universitätsklinikum Erlangen, Frauenklinik, Erlangen
| | - K Siam
- Medizincontrolling, Geschäftsbereich Medizinisches Management, Universitätsklinikum Münster, DRG-Research-Group, Münster
| | - J Babapirali
- Medizincontrolling, Geschäftsbereich Medizinisches Management, Universitätsklinikum Münster, DRG-Research-Group, Münster
| | - N Roeder
- Medizincontrolling, Geschäftsbereich Medizinisches Management, Universitätsklinikum Münster, DRG-Research-Group, Münster
| | - E Dausch
- Klinik für Frauenheilkunde und Geburtshilfe an der Unversität Regensburg, Caritas-Krankenhaus St. Josef, Regensburg
| | - T Hildebrandt
- Universitätsklinikum Erlangen, Frauenklinik, Erlangen
| | - P Hillemanns
- Medizinische Hochschule Hannover, Frauenklinik, Hannover
| | - M Nehmzow
- Universitätsklinikum Greifswald, Frauenklinik, Greifswald
| | - M Zygmunt
- Universitätsklinikum Greifswald, Frauenklinik, Greifswald
| | - D Piroth
- Universitätsklinikum Aachen, Frauenklinik, Aachen
| | - C Schem
- Universitätsklinikum Kiel, Frauenklinik, Kiel
| | - T Schwenzer
- Frauenklinik, Klinikum Dortmund Mitte, Dortmund
| | - K Friese
- Universitätsklinikum München, LMU, Frauenklinik, München
| | - D Wallwiener
- Universitätsklinikum Tübingen, Frauenklinik, Tübingen
| | - M W Beckmann
- Universitätsklinikum Erlangen, Frauenklinik, Erlangen
| |
Collapse
|
47
|
Farr A, Wuerstlein R, Neff J, Issels R, Lindner L, Belka C, Lauber K, Rauch J, Scheithauer H, Salat C, Pastorekova S, Takacova M, Friese K, Harbeck N. Identifikation von prädiktiven Biomarkern für Hyperthermie und Re-Bestrahlung beim loko-regionären Rezidiv des Mammakarzinoms. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
48
|
Wiest I, Heublein S, Mayr D, Friese K, Jeschke U, Dian D. Mucin-1 Antikörper im Vergleich bei Mamma-Karzinomen. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
49
|
Jückstock J, Sommer H, Dallmayr M, Mang J, Friese K. Komplette vorzeitige Plazentalösung bei vorbestehender Präeklampsie - Ein Fallbericht. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
50
|
Unverdorben L, Heublein S, Hutter S, Kuhn C, Friese K, Jeschke U. Expression von Galectinen in Spontan- und rezidivierenden Abort-Plazenten. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|